163 related articles for article (PubMed ID: 33809064)
1. A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma.
Fawwaz M; Mishiro K; Nishii R; Makino A; Kiyono Y; Shiba K; Kinuya S; Ogawa K
Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33809064
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR).
Fawwaz M; Mishiro K; Nishii R; Sawazaki I; Shiba K; Kinuya S; Ogawa K
Molecules; 2020 Jun; 25(12):. PubMed ID: 32599930
[TBL] [Abstract][Full Text] [Related]
3. PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Makino A; Miyazaki A; Tomoike A; Kimura H; Arimitsu K; Hirata M; Ohmomo Y; Nishii R; Okazawa H; Kiyono Y; Ono M; Saji H
Bioorg Med Chem; 2018 May; 26(8):1609-1613. PubMed ID: 29478801
[TBL] [Abstract][Full Text] [Related]
4.
Kimura H; Okuda H; Ishiguro M; Arimitsu K; Makino A; Nishii R; Miyazaki A; Yagi Y; Watanabe H; Kawasaki I; Ono M; Saji H
ACS Med Chem Lett; 2017 Apr; 8(4):418-422. PubMed ID: 28435529
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and initial
Fawwaz M; Mishiro K; Arwansyah A; Nishii R; Ogawa K
Bioimpacts; 2024; 14(1):27774. PubMed ID: 38327635
[TBL] [Abstract][Full Text] [Related]
6. JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.
Nishiya N; Sakamoto Y; Oku Y; Nonaka T; Uehara Y
World J Biol Chem; 2015 Nov; 6(4):409-18. PubMed ID: 26629323
[TBL] [Abstract][Full Text] [Related]
7. [Ionizing Radiation Reduces TKI Resistance Caused by T790M Mutation in NSCLC Cell Lines].
Li J; Wu X; Wang Z; Shen Z; Sun N; Zhu X
Zhongguo Fei Ai Za Zhi; 2015 Aug; 18(8):475-80. PubMed ID: 26302343
[TBL] [Abstract][Full Text] [Related]
8. Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer.
Sun P; Qu Y; Wang Y; Wang J; Wang X; Sheng J
J Cancer; 2021; 12(13):3900-3908. PubMed ID: 34093797
[TBL] [Abstract][Full Text] [Related]
9. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in
Hirano T; Yasuda H; Hamamoto J; Nukaga S; Masuzawa K; Kawada I; Naoki K; Niimi T; Mimasu S; Sakagami H; Soejima K; Betsuyaku T
Mol Cancer Ther; 2018 Apr; 17(4):740-750. PubMed ID: 29467275
[TBL] [Abstract][Full Text] [Related]
11. Compound 15c, a Novel Dual Inhibitor of EGFR
Chen G; Bao Y; Weng Q; Zhao Y; Lu X; Fu L; Chen L; Liu Z; Zhang X; Liang G
Front Pharmacol; 2019; 10():1533. PubMed ID: 31998131
[TBL] [Abstract][Full Text] [Related]
12. Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET.
Abourbeh G; Itamar B; Salnikov O; Beltsov S; Mishani E
EJNMMI Res; 2015; 5():4. PubMed ID: 25853010
[TBL] [Abstract][Full Text] [Related]
13. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis.
Chen LY; Molina-Vila MA; Ruan SY; Su KY; Liao WY; Yu KL; Ho CC; Shih JY; Yu CJ; Yang JC; Rosell R; Yang PC
Lung Cancer; 2016 Apr; 94():46-53. PubMed ID: 26973206
[TBL] [Abstract][Full Text] [Related]
14. The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis.
Liang H; Pan Z; Wang W; Guo C; Chen D; Zhang J; Zhang Y; Tang S; He J; Liang W;
J Thorac Dis; 2018 Apr; 10(4):2311-2320. PubMed ID: 29850136
[TBL] [Abstract][Full Text] [Related]
15. Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.
Ray P; Tan YS; Somnay V; Mehta R; Sitto M; Ahsan A; Nyati S; Naughton JP; Bridges A; Zhao L; Rehemtulla A; Lawrence TS; Ray D; Nyati MK
Oncotarget; 2016 Oct; 7(42):68597-68613. PubMed ID: 27612423
[TBL] [Abstract][Full Text] [Related]
16. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
[TBL] [Abstract][Full Text] [Related]
17. Targeting EGFR
Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of 99mTc-HYNIC-MPG as a novel SPECT radiotracer to detect EGFR-activating mutations in NSCLC.
Xiao Z; Song Y; Kai W; Sun X; Shen B
Oncotarget; 2017 Jun; 8(25):40732-40740. PubMed ID: 28489575
[TBL] [Abstract][Full Text] [Related]
19. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
20. WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple
Zheng Q; Chen D; Wang X; Yang Y; Zhao S; Dong X; Ma C; Zhang X; Duan H; Sun Y; Zheng S
Ann Transl Med; 2022 Jun; 10(12):696. PubMed ID: 35845484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
